Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
NCT ID: NCT02615496
Last Updated: 2017-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
716 participants
OBSERVATIONAL
2015-12-07
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Educational materials: Physicians
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
Educational materials: Patients
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet "Your guide to EYLEA," patient information leaflet, and audio CD.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet "Your guide to EYLEA," patient information leaflet, and audio CD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Licensed and practicing ophthalmologist
* Prescribed and administered aflibercept to at least one patient in the past 6 months
Patients eligibility:
* Patient has been administered aflibercept at least once within the last 6 months for any indication and is returning for a subsequent visit.
* Patient is aged 18 years or older.
* Patient is able to understand and sign the consent form and patient questionnaire.
* Patient can understand the native language of the country in which the study is being conducted.
* Patient has not participated in a clinical trial for the treatment of an aflibercept indication (e.g., wAMD, CRVO, or DME) in the past 12 months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RTI Health Solutions
OTHER
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , France
Many Locations, , Germany
Many Locations, , Italy
Many Locations, , Spain
Many Locations, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EY1301
Identifier Type: OTHER
Identifier Source: secondary_id
16526
Identifier Type: -
Identifier Source: org_study_id